US20140179802A1 - Fiber comprising a biodegradable polymer - Google Patents

Fiber comprising a biodegradable polymer Download PDF

Info

Publication number
US20140179802A1
US20140179802A1 US14/115,146 US201214115146A US2014179802A1 US 20140179802 A1 US20140179802 A1 US 20140179802A1 US 201214115146 A US201214115146 A US 201214115146A US 2014179802 A1 US2014179802 A1 US 2014179802A1
Authority
US
United States
Prior art keywords
fiber
biodegradable polymer
fiber according
poly
dimensional change
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/115,146
Other languages
English (en)
Inventor
Astrid Franken
George Mihov
Jens Christoph THIES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Assigned to DSM IP ASSETS B.V. reassignment DSM IP ASSETS B.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MIHOV, GEORGE, FRANKEN, ASTRID, THIES, JENS CHRISTOPH
Publication of US20140179802A1 publication Critical patent/US20140179802A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/44—Polyester-amides
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F1/00—General methods for the manufacture of artificial filaments or the like
    • D01F1/02—Addition of substances to the spinning solution or to the melt
    • D01F1/10—Other agents for modifying properties
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
    • D01F6/58—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products
    • D01F6/62—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products from polyesters
    • D01F6/625—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products from polyesters derived from hydroxy-carboxylic acids, e.g. lactones
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
    • D01F6/78—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from copolycondensation products
    • D01F6/82—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from copolycondensation products from polyester amides or polyether amides
    • D—TEXTILES; PAPER
    • D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10B2331/00—Fibres made from polymers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polycondensation products
    • D10B2331/02—Fibres made from polymers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polycondensation products polyamides
    • D—TEXTILES; PAPER
    • D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10B2331/00—Fibres made from polymers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polycondensation products
    • D10B2331/04—Fibres made from polymers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polycondensation products polyesters, e.g. polyethylene terephthalate [PET]
    • D10B2331/041—Fibres made from polymers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polycondensation products polyesters, e.g. polyethylene terephthalate [PET] derived from hydroxy-carboxylic acids, e.g. lactones
    • D—TEXTILES; PAPER
    • D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10B2401/00—Physical properties
    • D10B2401/12—Physical properties biodegradable

Definitions

  • the present invention relates to a fiber comprising a biodegradable polymer which undergoes dimensional change.
  • the present invention further relates to the use of the fiber as a drug delivery vehicle for the treatment of ophthalmic diseases.
  • the present invention also relates to a process for the manufacturing of a fiber via melt extrusion.
  • the present invention is based on the premise that the fibers can be formulated as drug delivery vehicles that may incorporate a bioactive agent for delivery to the anterior and/or posterior segment of the eye in a consistent and reliable manner. Release will depend on diffusion of bioactive agent through the polymer matrix and biodegradation of the polymer.
  • Intraocular delivery of drugs is a particular problem.
  • the eye is divided into two chambers; the anterior segment which is the front of the eye, and the posterior segment which is the back of the eye.
  • Diseases of the anterior segment are easier to treat with formulations such as eye drops because they can be applied topically.
  • glaucoma can be treated from the front of the eye.
  • Diseases of the retina such as diabetic retinopathy and macular degeneration, are located in the posterior segment and are difficult to treat because drugs applied topically, such as eye drops, typically do not penetrate to the back of the eye. Drugs for these diseases have customarily been delivered by injection directly into the back of the eye.
  • a fiber comprising a biodegradable polymer which undergoes dimensional change upon injection in the human or animal body wherein the dimensional change is a reduction of the surface area to volume ratio of a factor ranging from 1.05-10, preferably ranging from 1.25-5, more preferably ranging from 1.5-4, most preferably ranging from 2 to 10.
  • the fiber of the present invention thus has the ability to physically reshape or remodel after being injected into the human or animal body.
  • the dimensional change leads to an improved sustained release of bioactive agents due to the change of the surface to volume ratio, as diffusion of the bioactive agent from the bulk through the surface will be slowed by a relative reduction of the surface area. It moreover will decrease the number of injections needed to release the required amount of bioactive agents.
  • a further advantage is that a fibers can be injected that may even remodel into a drug delivery depot, which drug delivery depot as such would never be injectable.
  • the fiber according to the present invention is sized for injection via a pharmaceutical syringe needle having a bore of at least 25 Gauge.
  • the fibers may have a size ranging from 100-250 ⁇ m.
  • the fiber according to the present invention comprises a biodegradable polymer, preferably a biodegradable polymer which is an amorphous biodegradable polymer.
  • amorphous is meant that the molecules are oriented randomly and are intertwined, much like cooked spaghetti in which the polymer has a glasslike, transparent appearance. Whether or not polymers are amorphous can easily be determined by a man skilled in the art and may be measured using DSC or X-ray diffraction as is known in the art.
  • the biodegradable polymer preferably has a dry Tg ranging from 45 to 60 C. Further the biodegradable polymer preferably has a wet Tg below 37 C. Dry and wet Tg can be measured according to ASTM test method NO. D3418.
  • biodegradable polymers are polyesteramides or polyhydroxyacids (for example PLGA or poly L, D-lactic acid).
  • An example of an amorphous biodegradable polymer is a polyesteramide comprising alpha-amino acids, diols and dicarboxylic acids building blocks.
  • the fiber comprises a polyesteramide comprising alpha-amino acids, diols and dicarboxylic acids building blocks.
  • the fibers comprise a polyesteramide according to formula I
  • -m is about 0.01 to about 0.99; p is about 0.99 to about 0.01; and q is about 0.99 to 0.01; and wherein n is about 5 to about 350; and wherein
  • R 1 is independently selected from the group consisting of (C 2 -C 20 )alkylene, (C 2 -C 20 )alkenylene, —(R 9 —CO—O—R 10 —O—CO—R 9 )—, —CHR 11 —O—CO—R 12 —COOCR 11 — and combinations thereof;
  • R 3 and R 4 in a single co-monomer m or p, respectively, are independently selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl, (C 1 -C 6 )alkyl, —(CH 2 )SH, —(CH 2 ) 2 S(CH 3 ), —CH 2 OH, —CH(OH)CH 3 , —(CH 2 ) 4 NH 3 +, —(CH 2 ) 3 NHC( ⁇ NH 2 +)NH 2 , —CH 2 COOH, —(CH 2 )COOH, —CH 2 —CO—NH 2 , —CH 2 CH 2 —CO—NH 2 ,—CH 2 CH 2 COOH, CH 3 —CH 2 —CH(CH 3 )—, (CH 3 ) 2 —CH—CH—CH—
  • R 5 is selected from the group consisting of (C 2 -C 20 )alkylene, (C 2 -C 20 )alkenylene, alkyloxy or oligoethyleneglycol;
  • R 6 is a bicyclic-fragments of 1,4:3,6-dianhydrohexitols
  • R 7 is hydrogen, (C 6 -C 10 ) aryl, (C 1 -C 6 ) alkyl or a protecting group;
  • R 8 is independently (C 1 -C 20 ) alkyl or (C 2 -C 20 )alkenyl;
  • R 9 or R 10 are independently selected from C 2 -C 12 alkylene or C 2 -C 12 alkenylene.
  • R 11 or R 12 are independently selected from H, methyl, C 2 -C 12 alkylene or C 2 -C 12 alkenylene.
  • the fiber comprises a polyesteramide of Formula III, further disclosed as PEA-III-Ac Bz wherein m is about 0.3, p is about 0.45, q is about 0.25, n is about 5-100 and wherein
  • R 1 is (CH 2 ) 8 ;
  • R 3 and R 4 are selected from (CH 3 ) 2 —CH—CH 2 —;
  • R 5 is selected from (CH 2 ) 6 ,
  • R 6 is 1,4:3,6-dianhydrosorbitol (DAS);
  • R 7 is a benzyl protecting group
  • R 8 is (CH 2 ) 4 .
  • PEA-III-Ac Bz poly-8-[(L-Leu-DAS) 0.45 (L-Leu-6) 0.3 -[L-Lys(Bz)] 0.25 .
  • the fractions indicate overall fractions of the monomers in the synthesis.
  • alkyl refers to a straight or branched chain hydrocarbon group including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl, and the like.
  • alkenyl or “alkenylene”, refers to structural formulas herein to mean a divalent branched or unbranched hydrocarbon chain containing at least one unsaturated bond in the main chain or in a side chain.
  • alkynyl refers to straight or branched chain hydrocarbon groups having at least one carbon-carbon triple bond.
  • aryl is used with reference to structural formulas herein to denote a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic. Examples of aryl include, but are not limited to, phenyl, naphthyl, and nitrophenyl.
  • At least one of the alpha -amino acids used in the co-polymers is a natural alpha -amino acid.
  • the natural alpha-amino acid used in synthesis is L-phenylalanine.
  • the co-polymer contains the natural amino acid, leucine.
  • R 3 s and R 4 s By independently varying the R 3 s and R 4 s within variations of the two co-monomers as described herein, other natural alpha -amino acids can also be used, e.g., glycine (when the R 3 s or R 4 s are H), alanine (when the R 3 s or R 4 s are CH 3 ), valine (when the R 3 s or R 4 s are CH(CH 3 ) 2 ), isoleucine (when the R 3 s or R 4 s are CH(CH 3 )—CH 2 —CH 3 ), phenylalanine (when the R 3 s or R 4 s are CH 2 —C 6 H 5 ), lysine (when the R 3 s or R 4 s (CH 2 ) 4 —NH 2 ); or methionine (when the R 3 s or R 4 s are —(CH 2 ) 2 S(CH 3 ), and mixtures thereof.
  • the PEA co-polymers preferably have an average number molecular weight (Mn) ranging from 15,000 to 200,000 Daltons.
  • Mn average number molecular weight
  • the PEA co-polymers described herein can be fabricated in a variety of molecular weights and a variety of relative proportions of the two bis-(alpha amino acid)-containing units and optional Lysine-based monomer of the co-polymer.
  • the appropriate molecular weight for a particular use is readily determined by one of skill in the art.
  • a suitable Mn will be in the order of about 15,000 to about 150,000 Daltons, for example from about 30,000 to about 80,000 or from about 35,000 to about 75,000. Mn is measured via GPC in THF with polystyrene as standard.
  • biodegradable polymers include, but are not limited to, polyester amides, polyhydroxyalkanoates (PHA), poly(3-hydroxyalkanoates) such as poly(3-hydroxypropanoate), poly(3-hydroxybutyrate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(3-hydroxyheptanoate) and poly(3-hydroxyoctanoate), poly(4-hydroxyalkanaote) such as poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanote), poly(4-hydroxyheptanoate), poly(4-hydroxyoctanoate) and copolymers including any of the 3-hydroxyalkanoate or 4-hydroxyalkanoate monomers described herein or blends thereof, poly(D,L-lactide), poly(L-lactide), polyglycolide, poly(D,L-lactide-co-glycolide), poly(L-lactide-
  • PEO/PLA polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, poly(aspirin), biomolecules such as collagen, chitosan, alginate, fibrin, fibrinogen, cellulose, starch, collagen, dextran, dextrin, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosamino glycan (GAG), GAG derivatives, polysaccharide, elastin, chitosan, alginate, or combinations thereof.
  • GAG glycosamino glycan
  • the fiber according to the present invention may further comprise at least a bioactive agent.
  • the bioactive agent can be any agent which is a therapeutic, prophylactic, or diagnostic agent.
  • Such bioactive agent may include without any limitation small molecule drugs, peptides, proteins, DNA, cDNA, RNA, sugars, lipids and whole cells.
  • the bioactive agents can have antiproliferative or anti-inflammatory properties or can have other properties such as antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombotic, antimitotic, antibiotic, antiallergic, or antioxidant properties.
  • antiproliferative agents include rapamycin and its functional or structural derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), and its functional or structural derivatives, paclitaxel and its functional and structural derivatives.
  • rapamycin derivatives include ABT-578, 40-0-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-0-tetrazole-rapamycin.
  • paclitaxel derivatives include docetaxel.
  • antineoplastics and/or antimitotics examples include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia AND Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.).
  • antiplatelets examples include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Hb/nia platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax (Biogen, Inc., Cambridge, Mass.), calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck AND Co., Inc.
  • Angiomax Biogen, Inc., Cambridge, Mass.
  • anti-inflammatory agents including steroidal and nonsteroidal anti-inflammatory agents include biolimus, tacrolimus, dexamethasone, clobetasol, corticosteroids or combinations thereof.
  • cytostatic substances include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck AND Co., Inc., Whitehouse Station, N.J.).
  • An example of an antiallergic agent is permirolast potassium.
  • therapeutic substances or agents which may be appropriate include alpha-interferon, pimecrolimus, imatinib mesylate, midostaurin, and genetically engineered epithelial cells.
  • the foregoing substances can also be used in the form of prodrugs or co-drugs thereof.
  • the foregoing substances also include metabolites thereof and/or prodrugs of the metabolites.
  • the foregoing substances are listed by way of example and are not meant to be limiting.
  • the fiber according to the present invention can be used as a drug eluting vehicle especially for the treatment of disease in ophthalmology.
  • the invention further relates to the process for the manufacturing of the fiber according to the present invention comprising the following process steps;
  • the fiber is preferably manufactured via an extrusion process for example melt extrusion in which the biodegradable polymer and eventual additional compounds are homogenised using a Retsch cryomill.
  • the resulting powder is then filled into a pre-heated DSM Xplore micro-extruder with 5 cc barrel size and twin-screws which is connected to a micro fiber spin device.
  • the biodegradable polymer preferably has a residence time of 5-10 min at 120 C-140° C. before it is to be stretched into a fiber with diameter in the range of 100-250 ⁇ m.
  • the extrusion is normally performed under inert atmosphere in order to minimize the oxidative degradation of the polymer during the process. Under tension it is subsequently cooled at room temperature.
  • the obtained fiber is then preferably cut into pieces from for example 4 mm and may be sterilized via gamma radiation under cooling conditions.
  • FIG. 1 the dimensional change of the injected fiber according to the present invention is shown.
  • FIG. 1 relates to a PEA III fiber dry (A, 25 ⁇ magn.), in rabbit vitreous after 1 day (B, 50 ⁇ magn.) and after 14 days (C, 50 ⁇ magn.)
  • FIG. 2 relates to the release of active pharmaceutical ingredients (API) from PEA-III Ac Bz fibers.
  • FIG. 3 shows the evolution of the length, thickness and volume of a PEA-III Ac Bz fiber containing 30 wt % API.
  • FIG. 4 relates to a DSM Pharma extruder Xcelera for twin-screw micro extrusion with a speed of 1-250 rpm, a temperature range of 20-400° C., a marximal torque of 9000 N and a barrel capacity of 2 or 5 cm 3 equipped with DSM micro fiber spin device for thin fiber spinning.
  • FIG. 5 shows pictures of the fibers at 0, 0.5, 1 and 6 days taken using optic microscopy. On the optical light microscopy pictures is represented the size evolution of a PEA fiber containing 30 wt % of API, after immersion in PBS.
  • PEA-III-Ac Bz polymers are used in the following examples.
  • a more extended description of PEA-III-Ac Bz is poly-8-[(L-Leu-DAS) 0.45 (L-Leu-6) 0.3 -[L-Lys(Bz)] 0.25 .
  • Structure is given in Formula III. The fractions indicate overall fractions of the monomers in the synthesis.
  • Trietylamine (30.9 mL, 0.222 mole, 2.2 eq) and N,N-dimethylformamide (53.07 mL, 0.689 mole) were added to a mixture of Di-OSu-sebacinate (39.940 g, 0.1008 mole, 1.0 eq), L-leucine(6)-2TosOH (20.823 g, 0.0302 mole, 0.30 eq), L-leucine-(DAS)-2TosOH (32.503 g, 0.0453 mole, 0.45 eq) and L-lysine(Bz)-2TosOH (14.628 g, 0.0252 mole, 0.25 eq) in a nitrogen flushed 500 mL round bottomed flask equipped with a overhead stirrer at room temperature.
  • Di-OSu-sebacinate 39.940 g, 0.1008 mole, 1.0 eq
  • L-leucine(6)-2TosOH (20.823 g,
  • the obtained crude polymer mixture was precipitated in water in a 10:1 ratio (water:reaction mixture).
  • the polymer was collected and dissolved in ethanol (500 mL, 8.57 mole) and the procedure was repeated a second time.
  • the polymer was again dissolved in ethanol (500 mL, 8.57 mole) and precipitated in ethylacetate (5000 mL, 50.91 mole) by drop wise addition to a stirring solution.
  • the precipitated polymer was washed with two portions ethylacetate (100 mL, 1.00 mole), dried and dissolved in ethanol (500 mL, 8.57 mole) and filtered over a 0.2 ⁇ m PTFE membrane filter.
  • the filtered polymer solution was dried under reduced pressure at 65° C.
  • the resulting fibers of a diameter of ⁇ 300 pm were cut with a length of 10 mm and individually weight.
  • the release was performed at 37° C. in PBS.
  • PBS was refreshed at each time point and quantity of API was measured in triplicate, by HPLC.
  • these fibers undergo remodeling (Process 1) Resulting release is presented in the FIG. 2
  • This example shows that a fiber remodeling inducing a decrease of the surface to volume ratio will influence and slow down the release of API from the fiber.
  • the resulting fibers were cut and placed into PBS at 37° C. Length and thickness were monitored by optical light microscopy.
  • FIG. 3 represents the evolution of length, thickness, and volume of a PEA Ill Ac Bz fiber, containing 30 wt % API processed as described in example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Textile Engineering (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing & Machinery (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Artificial Filaments (AREA)
  • Materials For Medical Uses (AREA)
US14/115,146 2011-05-02 2012-05-02 Fiber comprising a biodegradable polymer Abandoned US20140179802A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11164501 2011-05-02
EP11164501.6 2011-05-02
PCT/EP2012/058036 WO2012150265A1 (fr) 2011-05-02 2012-05-02 Fibre comprenant un polymère biodégradable

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/058036 A-371-Of-International WO2012150265A1 (fr) 2011-05-02 2012-05-02 Fibre comprenant un polymère biodégradable

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/975,156 Continuation US20160102176A1 (en) 2011-05-02 2015-12-18 Fiber comprising a biodegradable polymer
US14/975,156 Division US20160102176A1 (en) 2011-05-02 2015-12-18 Fiber comprising a biodegradable polymer

Publications (1)

Publication Number Publication Date
US20140179802A1 true US20140179802A1 (en) 2014-06-26

Family

ID=44343199

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/115,146 Abandoned US20140179802A1 (en) 2011-05-02 2012-05-02 Fiber comprising a biodegradable polymer
US14/975,156 Abandoned US20160102176A1 (en) 2011-05-02 2015-12-18 Fiber comprising a biodegradable polymer
US15/484,488 Active US10123972B2 (en) 2011-05-02 2017-04-11 Fiber comprising a biodegradable polymer

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/975,156 Abandoned US20160102176A1 (en) 2011-05-02 2015-12-18 Fiber comprising a biodegradable polymer
US15/484,488 Active US10123972B2 (en) 2011-05-02 2017-04-11 Fiber comprising a biodegradable polymer

Country Status (4)

Country Link
US (3) US20140179802A1 (fr)
EP (1) EP2705182B1 (fr)
JP (1) JP6135870B2 (fr)
WO (1) WO2012150265A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095619B2 (en) 2006-04-17 2015-08-04 Abbott Cardiovascular Systems Inc. Polyesteramide platform for site specific drug delivery
WO2017091749A1 (fr) * 2015-11-25 2017-06-01 Incept, Llc Dispositifs d'administration de médicaments à changement de forme et procédés
US9789189B2 (en) 2012-10-02 2017-10-17 Dsm Ip Assets Bv Drug delivery composition comprising proteins and biodegradable polyesteramides
US9873764B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Particles comprising polyesteramide copolymers for drug delivery
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US10434071B2 (en) 2014-12-18 2019-10-08 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
US20200306182A1 (en) * 2019-03-05 2020-10-01 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101646561B1 (ko) * 2014-12-26 2016-08-12 도레이케미칼 주식회사 내열성이 우수한 섬유용 수용성 폴리에스테르, 그 제조방법 및 이를 포함하는 복합섬유

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035938A2 (fr) * 2005-09-22 2007-03-29 Medivas, Llc FORMULES DE POLY(ESTER AMIDE) ET DE POLY(ESTER URÉTHANE) CONTENANT DES DIESTERS DE BIS-(α-AMINO)-DIOL ET MÉTHODES D'EMPLOI

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200410714A (en) * 2002-08-07 2004-07-01 Smithkline Beecham Corp Electrospun amorphous pharmaceutical compositions
CA2585740A1 (fr) * 2004-10-28 2006-05-11 Medivas, Llc Pansement pour blessures bioactif, dispositifs implantables et procedes d'utilisation
US20060159918A1 (en) * 2004-12-22 2006-07-20 Fiber Innovation Technology, Inc. Biodegradable fibers exhibiting storage-stable tenacity
US8652504B2 (en) * 2005-09-22 2014-02-18 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
JP2009516757A (ja) * 2005-10-21 2009-04-23 メディバス エルエルシー ポリ（エステルウレア）ポリマーおよび使用法
US8974815B2 (en) * 2005-12-16 2015-03-10 Cornell University Fibrous membrane for biomedical application based on poly(ester-amide)s
CA2649672C (fr) * 2006-05-02 2015-07-07 Medivas, Llc Administration d'agents ophtalmiques a l'exterieur et a l'interieur de l'oeil
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035938A2 (fr) * 2005-09-22 2007-03-29 Medivas, Llc FORMULES DE POLY(ESTER AMIDE) ET DE POLY(ESTER URÉTHANE) CONTENANT DES DIESTERS DE BIS-(α-AMINO)-DIOL ET MÉTHODES D'EMPLOI

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603943B2 (en) 2006-04-17 2017-03-28 Abbott Cardiovascular Systems Inc. Polyesteramide platform for site specific drug delivery
US9095619B2 (en) 2006-04-17 2015-08-04 Abbott Cardiovascular Systems Inc. Polyesteramide platform for site specific drug delivery
US9873764B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Particles comprising polyesteramide copolymers for drug delivery
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9896544B2 (en) 2011-06-23 2018-02-20 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9963549B2 (en) 2011-06-23 2018-05-08 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9789189B2 (en) 2012-10-02 2017-10-17 Dsm Ip Assets Bv Drug delivery composition comprising proteins and biodegradable polyesteramides
US10888531B2 (en) * 2014-12-18 2021-01-12 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitivity drugs
US11202762B2 (en) * 2014-12-18 2021-12-21 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitivity drugs
US10434071B2 (en) 2014-12-18 2019-10-08 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
US20200038337A1 (en) * 2014-12-18 2020-02-06 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
US10420724B2 (en) 2015-11-25 2019-09-24 Incept, Llc Shape changing drug delivery devices and methods
US10786462B2 (en) 2015-11-25 2020-09-29 Incept, Llc Shape changing drug delivery devices and methods
WO2017091749A1 (fr) * 2015-11-25 2017-06-01 Incept, Llc Dispositifs d'administration de médicaments à changement de forme et procédés
AU2016361579B2 (en) * 2015-11-25 2022-08-04 Incept, Llc Shape changing drug delivery devices and methods
US11413250B2 (en) 2015-11-25 2022-08-16 Incept, Llc Shape changing drug delivery devices and methods
US11938223B2 (en) 2015-11-25 2024-03-26 Incept, Llc Shape changing drug delivery devices and methods
US20200306182A1 (en) * 2019-03-05 2020-10-01 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders

Also Published As

Publication number Publication date
US20170216201A1 (en) 2017-08-03
EP2705182A1 (fr) 2014-03-12
WO2012150265A1 (fr) 2012-11-08
EP2705182B1 (fr) 2018-10-31
US20160102176A1 (en) 2016-04-14
JP2014517881A (ja) 2014-07-24
US10123972B2 (en) 2018-11-13
JP6135870B2 (ja) 2017-05-31

Similar Documents

Publication Publication Date Title
US10123972B2 (en) Fiber comprising a biodegradable polymer
US9896544B2 (en) Biodegradable polyesteramide copolymers for drug delivery
US9095619B2 (en) Polyesteramide platform for site specific drug delivery
US20200087819A1 (en) Fibers comprising polyesteramide copolymers for drug delivery
EP2934614B1 (fr) Revêtement comprenant des copolymères de polyesteramide pour l'administration de médicaments
US11891726B2 (en) Fibers comprising polyesteramide copolymers for drug deliver
US9873765B2 (en) Biodegradable polyesteramide copolymers for drug delivery
US20220396698A1 (en) Polyesteramide copolymers possessing high glass transition temperatures

Legal Events

Date Code Title Description
AS Assignment

Owner name: DSM IP ASSETS B.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRANKEN, ASTRID;MIHOV, GEORGE;THIES, JENS CHRISTOPH;SIGNING DATES FROM 20131104 TO 20131105;REEL/FRAME:032501/0745

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION